Elevate Your Diabetes Management Program with SequelConnect

Partner with us to provide a complementary, innovative solution that fills the insulin therapy gap in your existing diabetes management offering. Enhance your value proposition without disrupting your current programs.

Addressing the Full Spectrum of Diabetes Care Needs is Challenging

Today's diabetes management programs are effective for many members. But channel partners often face key challenges in addressing the full spectrum of care needs related to diabetes for their clients.

The Insulin Therapy Gap

While your comprehensive diabetes management programs excel at driving behavioral change, approximately 25% of people with diabetes require insulin therapy.¹ This represents a specialized segment that could benefit from additional technological support.

Innovation Expectations

Your clients continuously seek fresh, innovative solutions to enhance their benefits packages, creating pressure to regularly introduce new offerings that demonstrate your commitment to cutting-edge care.

Engagement and Retention Challenges

Maintaining high engagement rates across diverse diabetes populations presents ongoing challenges, particularly among insulin-dependent members who face unique daily management burdens and require unique solutions.

The Solution

Introducing SequelConnect: Your Innovative Insulin Management Program

SequelConnect acts as an addition — not a replacement — to an organization’s existing diabetes strategy by identifying high-cost members who use insulin and providing a seamless path to advanced diabetes management in the form of Automated Insulin Delivery (AID) Systems.

A True Extension of Your Care Team

Human resources professionals and benefits providers can now offer a tangible solution that makes a real difference. With SequelConnect, you become a powerful link in the care continuum-bringing advanced diabetes technology to those who need it.

Minimizing Financial Barriers for Members

Most members will pay $0 the 1st month for the twiist™ AID System and no more than $50 each month thereafter⁵. There's no obligation to continue and no additional cost per member per month, giving them the freedom to experience the benefits without financial pressure.

The twiist Automated Insulin Delivery (AID) System is for people with type 1 diabetes, 6 years of age and above, available with a prescription, only in the U.S. Currently pursuing type 2 indication.

Key Program Elements

The Perfect Complement to Your Diabetes Care Ecosystem

SequelConnect seamlessly integrates with your existing diabetes management program, creating a flexible partnership that enhances—rather than competes with—your current offerings:

Flexible Integration Options

Whether fully integrated into your platform or offered as a complementary referral pathway, we adapt to your preferred partnership model

Co-Branding Opportunities

Leverage SequelConnect as an extension of your established care ecosystem with customizable branding options

Differentiated Value Proposition

Equip your sales team with an innovative solution that addresses a specialized care need and strengthens client retention

Elevated Program Outcomes

Offer more to your clients and help improve your overall diabetes program metrics by addressing the specialized needs of insulin-dependent members

The program features outlined above are included as part of the twiist AID System experience. Features may differ if a member is prescribed a different AID system.

Introducing the twiist™ AID System: Breakthrough Technology for Your Members

The centerpiece of SequelConnect is the innovative twiist™ Automated Insulin Delivery (AID) System, representing a breakthrough in diabetes care technology.³

Innovative Insulin Therapy

Every 5 minutes, twiist makes 72 sequential glucose predictions to create a 6-hour glucose forecast based on therapy settings, recent history of insulin delivery, recent history of carb entries and recent continuous glucose monitor (CGM) readings.

Breakthrough Technology

The iiSure™ Technology in the twiist AID System precisely measures the volume of each microdose by taking 4 direct measurements to ensure accuracy of insulin delivery.

The twiist Automated Insulin Delivery (AID) System is for people with type 1 diabetes, 6 years of age and above, available with a prescription, only in the U.S. Pursuing type 2 indication.

The twiist™ AID System: Breakthrough Technology Made Accessible

Simplicity

Simple Implementation with Minimal Contracting

Partnering with SequelConnect requires minimal administrative effort, with streamlined contracting, turnkey implementation, and comprehensive support throughout the onboarding process:

Ready-to-deploy member identification and enrollment processes

Pre-built communication materials that can be co-branded

Integrated reporting to track program impact and ROI

Dedicated support team for seamless implementation

Learn More

Effective

Outcomes You Can Measure

Uncover the missing piece to your current diabetes strategy and transform it from great to phenomenal. How? SequelConnect targets your highest-cost members who drive the majority of diabetes-related medical spend, creating the potential for transformative outcomes.

Expected savings per member, per year

$18.7K

Medical cost savings based on an avoided hospitalization rate of 80%.³

Real-world demonstration of outcomes

6.5% A1C

Sustained average level as a result from a real-world study.⁴

Results obtained with the Loop algorithm using a non-twiist device.

Learn More

SAVINGS CALCULATOR

See How Much Employer Can Save With SequelConnect

Discover the impact SequelConnect can have on your company's bottom line. Use our calculator to estimate your organization's potential cost savings when implementing SequelConnect, our innovative diabetes management program.

How many lives does your organization cover?

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

The estimated annual savings amount calculated is based on the estimated number of covered lives, average percentage of the U.S. population living with diabetes requiring insulin, and estimated enrollment rate. Please contact Sales for details and exact calculations as it relates to your business. Actual results may vary.

Close the Gap in Your Diabetes Strategy Today

You've done a great job building a diabetes management program. Now it's time to make it phenomenal. SequelConnect provides the missing pieces to help your insulin-dependent members achieve better health¹ while reducing your overall costs.

Fang M, et al. Trends in Diabetes Treatment and Control in U.S. Adults, 1999 -2018. N Engl J Med 2021;384(23):2219 -28
The twiist™ Savings Program is available to individuals with a valid prescription and commercial insurance that covers twiist. Eligible participants can receive a Starter Kit for $0 and pay no more than $50 for Refill Kits. This offer is not valid for individuals enrolled in Medicare, Medicaid, or any other federal or state programs, or for cash-paying patients and non-covered claims. It is available only in the U.S. and is not valid in Puerto Rico, U.S. Territories, or where prohibited by law. While most commercially insured participants qualify for the $50 Refill Kit offer, those with high-deductible plans who haven't met their deductible may pay more than $50 per Refill Kit until their deductible is met. The maximum benefit is $200 per Refill Kit for covered claims. Terms are subject to change. Call us at 1-877-489-4478 or contact your insurance provider to confirm coverage.
Sequel Med Tech - twiist Automated Insulin Delivery (AID) System Powered by Tidepool User Guide. The twiist Automated Insulin Delivery (AID) System is for people with type 1 diabetes, 6 years of age and above, available with a prescription, only in the U.S. Visit twiist.com/safety for important safety information.
Sequel - Data on File
Results obtained with the Loop algorithm using a non-twiist device. Lum JW, et al. A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System. Diabetes Technol Ther 2021;23(5):367–75.